

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

CLAIMS

1. Purified natural or synthetic polypeptide, characterized by the fact that it responds to the amino acid sequence SEQ ID

NO: 1:

SUB A

Met	Ala	Gly	Glu	Leu	Thr	Pro	Glu	Glu	Glu	10
Ala	Gln	Tyr	Lys	Lys	Ala	Phe	Ser	Ala	Val	20
Asp	Thr	Asp	Gly	Asn	Gly	Thr	Ile	Asn	Ala	30
Gln	Glu	Leu	Gly	Ala	Ala	Leu	Lys	Ala	Thr	40
Gly	Lys	Asn	Leu	Ser	Glu	Ala	Gln	Leu	Arg	50
Lys	Leu	Ile	Ser	Glu	Val	Asp	Ser	Asp	Gly	60
Asp	Gly	Glu	Ile	Ser	Phe	Gln	Glu	Phe	Leu	70
Thr	Ala	Ala	Arg	Lys	Ala	Arg	Ala	Gly	Leu	80
Glu	Asp	Leu	Gln	Val	Ala	Phe	Arg	Ala	Phe	90
Asp	Gln	Asp	Gly	Asp	Gly	His	Ile	Thr	Val	100
Asp	Glu	Leu	Arg	Arg	Ala	Met	Ala	Gly	Leu	110
Gly	Gln	Pro	Leu	Pro	Gln	Glu	Glu	Leu	Asp	120
Ala	Met	Ile	Arg	Glu	Ala	Asp	Val	Asp	Gln	130
Asp	Gly	Arg	Val	Asn	Tyr	Glu	Glu	Phe	Ala	140
Arg	Met	Leu	Ala	Gln	Glu					146

2. Polypeptide according to claim 1, wherein it is purified from mammals.

3. Polypeptide according to any of the preceding claims, wherein it is purified from the skin of mammals.

SUB #2
4. Polypeptide according to any of the preceding claims, wherein it is purified from human skin.

5. Polypeptide according to any of the preceding claims, wherein it is purified from the human epidermis.

6. Natural or synthetic polypeptide whose sequence in part consists of the sequence of polypeptide as described in claim 1.

7. Polypeptide according to any of the preceding claims, wherein it has a theoretical isoelectric point between 1 and 6, particularly between 3 and 5.

8. Polypeptide according to any of the preceding claims, wherein it has a theoretical molecular weight of between 13 and 17 kilodaltons (kD), particularly between 14 and 16 kilodaltons (kD).

9. Mixture of polypeptides obtained from the proteolysis of polypeptide as described in claims 1 to 8.

10. Polypeptide according to any of the preceding claims, wherein in its primary sequence, it has at least one calcium-fixing site.

11. Polypeptide according to any of the preceding claims, wherein it fixes calcium.

12. Composition wherein it comprises in a physiologically acceptable medium at least one polypeptide as defined in any of claims 1 to 11.

13. Composition intended to regulate the impairments of epidermal, normal or pathological proliferation or differentiation, wherein it comprises, in a cosmetically acceptable medium, at least one polypeptide as defined in any of claims 1 to 11.

14. Composition for treating dry skin, hyperkeratosis, parakeratosis, psoriasis, ichthyoses, neoplasias, wherein in a

SUB
P2

21. Isolated deoxyribonucleic acid fragment that codes for the polypeptide as defined in one of claims 1 to 11.

22. Isolated deoxyribonucleic acid fragment that comprises at least the nucleotide sequence that codes SEQ ID NO: 2 below:

AATCCCAGGA	TCCCTGCGGC	TGCCTGCACT	CTGGACCACG	40
AGCTCTGAGA	GCAGCAGGTT	GAGGGCCGGT	GGGCAGCAGC	80
TCGGAGGCTC	CGCGAGGTGC	AGGAGACGCA	GGCATGGCCG	120
GTGAGCTGAC	TCCTGAGGAG	GAGGCCCAGT	ACAAAAAGGC	160
TTTCTCCGCG	GTTGACACGG	ATGGAAACGG	CACCATCAAT	200
GCCCAGGAGC	TGGGCGCGGC	GCTGAAGGCC	ACGGGCAAGA	240
ACCTCTCGGA	GGCCCAGCTA	AGGAAACTCA	TCTCCGAGGT	280
TGACAGCGAC	GGCGACGGCG	AAATCAGCTT	CCAGGAGTTC	320
CTGACGGCGG	CAAGGAAGGC	CAGGGCCGGC	CTGGAGGACC	360
TGCAGGTCGC	CTTCCGCGCC	TTCGACCAGG	ATGGCGACGG	400
CCACATCACC	GTGGACGAGC	TCAGGCGGGC	CATGGCGGGG	440
CTGGGGCAGC	CGCTGCCGCA	GGAGGAGCTG	GACGCCATGA	480
TCCGCGAGGC	CGACGTGGAC	CAGGACGGGC	GGGTGAACTA	520
CGAGGAGTTC	GCGAGGATGC	TCGCCAGGA	GTGAGGCTCC	560
CCGCCTGTGT	CCCCCTGGCT	GCGCTCTGAG	CCTTCAGGGC	600
CACCGCCCGC	TGCTGCTTTT	GTGCTGGGAC	TCTCCGGGGA	640
AACCTGGTCG	GTGGATGGGA	AACTGCCTCC	CCCTGGGAGG	680
AAGGCTTTGC	GCTCCGGGGC	CTGGATGCGG	CGCCCTCGGG	720
CCGCCTGCGA	GCCCCTCTCT	GCCTTCAGAC	CTTGGGCAGA	760
AGGAGGCCTC	CTTGGGCCTG	GTCCCCCTTT	GCCCTGCAGT	800
GGAATGAGGG	CCCCTTAACC	CCGCATTGAT	CTAAATAAAG	840
GACTGCCGAG	TTCCAAAA			858

physiologically acceptable medium, it comprises at least one polypeptide as defined in any of claims 1 to 11.

15. Composition according to any of claims 12 to 14, wherein it is intended for a cosmetic or pharmaceutical application.

16. Use of at least one polypeptide as defined in any of claims 1 to 11, in a composition or for the preparation of a composition, whereby the polypeptide or the composition is intended to treat dry skin, hyperkeratosis, parakeratosis, psoriasis, ichthyoses, neoplasias.

17. Use of at least one polypeptide as defined in any of claims 1 to 11, in a composition or for the preparation of a composition, whereby the polypeptide or the composition is intended to regulate the transglutaminases.

18. Use of at least one polypeptide as defined in any of claims 1 to 11, in a composition or for the preparation of a composition, whereby the polypeptide or the composition is intended to regulate transglutaminase 3.

19. Use of at least one polypeptide as defined in any of claims 1 to 11, in a composition or for the preparation of a composition, whereby the polypeptide or the composition is intended to regulate the formation of the corneal layer of the epidermis.

20. Process of cosmetic treatment for treating dry skin, hyperkeratosis, parakeratosis, psoriasis, ichthyoses, neoplasias, wherein a cosmetic composition as described in claims 12 to 15 is applied on the skin of the subject to be treated.

23. Isolated deoxyribonucleic acid fragment that comprises all or part of the nucleotide sequence as described in claim 22.

24. Cosmetic or pharmaceutical composition, wherein it comprises, in a physiologically acceptable medium, at least one nucleotide sequence as described in any of claims 22 or 23.

25. Use of at least one deoxyribonucleic acid sequence as described in any of claims 22 or 23 for preparing a polypeptide or a mixture of polypeptides.

26. Recombinant expression vector that contains all or part of the nucleotide sequence that codes SEQ ID NO: 2.

27. Recombinant protein that corresponds to all or part of the sequence SEQ ID NO: 1.

28. Recombinant protein that is obtained by expression of an expression vector pGex-2T that contains all or part of the sequence that codes SEQ ID NO: 2.

29. Use of at least one deoxyribonucleic acid sequence as described in any of claims 22 or 23 for preparing a ribonucleic acid.

30. Use of at least one isolated polypeptide or at least one of its proteolysis fragments or any synthetic peptide as described in claims 1 to 11 for preparing or purifying any molecule that can be bound specifically to said purified polypeptide or to said purified proteolysis fragments or to said synthetic peptide.

31. Use of at least one isolated polypeptide or at least one of its proteolysis fragments or any synthetic peptide as

described in claims 1 to 11 for preparing or purifying antiserums or specific monoclonal antibodies.

32. Polyclonal or monoclonal antibodies, wherein said antibody recognizes specifically the polypeptide as described in claims 1 to 11.